SCHEMBL874504

SCHEMBL874504

C=CCc1ccc(O)c(OC)c1Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP3A4 P08684 1/20 0.42
AR P10275 1/20 0.42
PTGS1 P23219 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
GABRA1 P14867 3/20 0.40
GABRB2 P47870 3/20 0.40
CNR2 P34972 1/20 0.40
PTPN1 P18031 1/20 0.37
BCL2 P10415 1/20 0.37
BCL2L1 Q07817 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029483 0.88 PPARG (0.44) ALOX5ALDH1A1CYP3A4ARPTGS1
SCHEMBL2843447 0.84 ALOX5 (0.46) ALOX5ALDH1A1CYP3A4ARPTGS1
SCHEMBL7948321 0.82 BCL2 (0.41) ALOX5CYP3A4BCL2BCL2L1
SCHEMBL11876989 0.81 GABRA1 (0.42) ALOX5ALDH1A1CYP3A4GABRA1GABRB2
SCHEMBL1173287 0.81 ALOX5 (0.44) ALOX5ALDH1A1CYP3A4ARPTGS1
Salicylic Acid SCHEMBL11345117 0.80 CYP2C9 (0.45) ALOX5ALDH1A1CYP3A4ARGABRA1
SCHEMBL2030041 0.78 PDE4B (0.47) ALOX5ALDH1A1CYP3A4ARPTGS1
SCHEMBL11553229 0.78 ALOX5 (0.42) ALOX5ALDH1A1CYP3A4ARPTGS1
SCHEMBL28069115 0.78 TRPM8 (0.42) ALOX5ALDH1A1CYP3A4ARPTGS1
SCHEMBL29101603 0.77 ALOX5 (0.41) ALOX5ALDH1A1CYP3A4ARPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4356894-A1 SUSTAINABLE PRODUCT WITH MALODORS Beiersdorf AG (DE) 2024-04-24 EP claimed
EP-1894603-B1 Encapsulation of bulky fragrance molecules TAKASAGO PERFUMERY CO LTD (JP) 2014-11-19 EP claimed
US-8609600-B2 Encapsulation of bulky fragrance molecules TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-12-17 US claimed
JP-63167791-A None JP disclosed
US-20240408090-A1 Methods Of Treating Dyskinesia And Related Disorders MELIOR PHARMACEUTICALS II, LLC 2024-12-12 US disclosed
US-12048697-B2 Methods of treating dyskinesia and related disorders MELIOR PHARMACEUTICALS II, LLC (US) 2024-07-30 US disclosed
EP-4356894-A1 SUSTAINABLE PRODUCT WITH MALODORS Beiersdorf AG (DE) 2024-04-24 EP disclosed
US-20220331320-A1 Methods Of Treating Dyskinesia And Related Disorders MELIOR PHARMACEUTICALS II, LLC 2022-10-20 US disclosed
US-11351169-B2 Methods of treating dyskinesia and related disorders MELIOR PHARMACEUTICALS II, LLC (US) 2022-06-07 US disclosed
CN-108699493-B Detergent composition 狮王株式会社 2021-10-08 CN disclosed
CN-111944609-A Perfume composition with plum blossom fragrance 北京林业大学 2020-11-17 CN disclosed
EP-1894603-A1 Encapsulation of bulky fragrance molecules Takasago International Corporation (JP) 2008-03-05 EP disclosed
EP-1827370-A1 HAIR PROCESSING AGENT AND METHOD FOR PERMANENT WAVING HAIR Showa Denko K.K. (JP) 2007-09-05 EP disclosed
EP-1765139-A1 ROLLER FOR PROVIDING BENEFITS TO FABRIC The Procter and Gamble Company (US) 2007-03-28 EP disclosed
US-20060165622-A1 Deodorant composition TAKASAGO INTERNATIONAL CORPORATION (JP) 2006-07-27 US disclosed
WO-2006068276-A1 HAIR PROCESSING AGENT AND METHOD FOR PERMANENT WAVING HAIR SHOWA DENKO K.K. (JP) 2006-06-29 WO disclosed
WO-2006010087-A1 ROLLER FOR PROVIDING BENEFITS TO FABRIC THE PROCTER & GAMBLE COMPANY (US) 2006-01-26 WO disclosed
US-20060005333-A1 Roller for providing benefits to fabric PROCTER & GAMBLE COMPANY, THE 2006-01-12 US disclosed
EP-1561476-A1 DEODORANT COMPOSITION Takasago International Corporation (JP) 2005-08-10 EP disclosed
JP-S63167791-A MUTATION INHIBITOR KANEBO LTD 1988-07-11 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220331320-A1 Methods Of Treating Dyskinesia And Related Disorders SLC6A3, CHAT, ACHE ALOX5 1729/4885ALDH1A1 1203/4885CYP3A4 2524/4885
US-20240408090-A1 Methods Of Treating Dyskinesia And Related Disorders SLC6A3, CHAT, ACHE ALOX5 1729/4885ALDH1A1 1203/4885CYP3A4 2524/4885
US-12048697-B2 Methods of treating dyskinesia and related disorders SLC6A3, CHAT, ACHE ALOX5 1729/4885ALDH1A1 1203/4885CYP3A4 2524/4885
US-11351169-B2 Methods of treating dyskinesia and related disorders SLC6A3, CHAT, ACHE ALOX5 1729/4885ALDH1A1 1203/4885CYP3A4 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.